Providence Wealth Advisors LLC Grows Stock Position in Seres Therapeutics, Inc. (NASDAQ:MCRB)

Providence Wealth Advisors LLC grew its position in Seres Therapeutics, Inc. (NASDAQ:MCRB) by 29.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 98,500 shares of the biotechnology company’s stock after acquiring an additional 22,250 shares during the quarter. Providence Wealth Advisors LLC owned about 0.06% of Seres Therapeutics worth $93,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in MCRB. Point72 DIFC Ltd purchased a new position in shares of Seres Therapeutics in the second quarter valued at approximately $64,000. Virtu Financial LLC purchased a new position in shares of Seres Therapeutics in the first quarter valued at approximately $73,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Seres Therapeutics in the second quarter valued at approximately $92,000. Vontobel Holding Ltd. purchased a new position in shares of Seres Therapeutics in the third quarter valued at approximately $374,000. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Seres Therapeutics by 42.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock valued at $708,000 after acquiring an additional 222,771 shares in the last quarter. Hedge funds and other institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Stock Up 4.3 %

NASDAQ:MCRB opened at $0.92 on Friday. Seres Therapeutics, Inc. has a 52 week low of $0.54 and a 52 week high of $2.05. The stock’s fifty day moving average is $0.81 and its two-hundred day moving average is $0.90. The company has a market capitalization of $156.23 million, a P/E ratio of -3.98 and a beta of 2.06.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on MCRB. JPMorgan Chase & Co. downgraded Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Thursday, October 24th. StockNews.com downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. Chardan Capital reiterated a “buy” rating and set a $1.25 price objective on shares of Seres Therapeutics in a research report on Wednesday, November 13th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $10.00 price objective on shares of Seres Therapeutics in a research report on Thursday, November 14th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $5.08.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.